ACC House Call: Future TAVR Advances


How will heart valve options refine and progress over the coming year?

For all its tout as a forward-looking practice, transcatheter aortic valve replacement (TAVR) has been prevalent in invasive cardiology for 2 decades now. But experts are not done refining the most popular TAVR options and the overall procedure.

In a special edition House Call video interview with HCPLive®, Gilbert H. Tang, MD, Associate Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai and Surgical Director of the Structural Heart Program for the Mount Sinai Health System, followed up his breakdown of new Align TAVR data with a talk on how SAPIEN 3, Evolut, and ACURATE-neo transcatheter may continue to progress in the coming year.

Tang also shares how he thinks the newest TAVR research and discussion will be shaped in time for the American College of Cardiology (ACC) 2021 Scientific Sessions this time next year.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
© 2024 MJH Life Sciences

All rights reserved.